If your loved one with moderate AD is taking donepezil 10 mg, NAMZARIC may:
There is no evidence that NAMZARIC prevents or slows the underlying disease process in patients with AD.
To help start a conversation with the healthcare provider and see if NAMZARIC is right for your loved one, view and print this NAMZARIC brochure.
If your loved one is taking a different AChEI—Exelon® Patch (rivastigmine)* or Razadyne® (galantamine HBr)†—or a dose other than 10 mg of donepezil HCl, ask the healthcare provider about combination therapy and if adding NAMENDA XR to your loved one’s current treatment may be right for him or her.
Exelon® is a registered trademark of Novartis AG Corp.
Razadyne® is a registered trademark of Johnson & Johnson.
NAMZARIC is a prescription medicine approved to treat moderate to severe Alzheimer’s disease in patients who are taking donepezil hydrochloride 10 mg, the active ingredient in Aricept®.
There is no evidence that NAMZARIC prevents or slows the underlying disease process in patients with Alzheimer's disease.
NAMZARIC should not be taken by anyone who: has an allergy to memantine HCl, donepezil HCl, medicines that contain piperidines, or any of the ingredients in NAMZARIC.
Before taking NAMZARIC, tell the doctor about all of the patient’s medical conditions, including:
Tell the doctor about all the medicines the patient takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
NAMZARIC may cause serious side effects, including:
The most common side effects of memantine HCl include: headache, diarrhea, and dizziness.
The most common side effects of donepezil HCl include: diarrhea, not wanting to eat (anorexia), and bruising.
These are not all the possible side effects of NAMZARIC.
Please see full Prescribing Information, including Patient Information.
Aricept® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
NAMZARIC is a prescription medicine approved to treat moderate to severe Alzheimer’s disease in patients who are taking donepezil hydrochloride 10 mg, the active ingredient in Aricept®.
There is no evidence that NAMZARIC prevents or slows the underlying disease process in patients with Alzheimer's disease.
NAMZARIC is a prescription medicine approved to treat moderate to severe Alzheimer’s disease in patients who are taking donepezil hydrochloride 10 mg, the active ingredient in Aricept®.
There is no evidence that NAMZARIC prevents or slows the underlying disease process in patients with Alzheimer's disease.
NAMZARIC should not be taken by anyone who: has an allergy to memantine HCl, donepezil HCl, medicines that contain piperidines, or any of the ingredients in NAMZARIC.
Before taking NAMZARIC, tell the doctor about all of the patient’s medical conditions, including:
Tell the doctor about all the medicines the patient takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
NAMZARIC may cause serious side effects, including:
The most common side effects of memantine HCl include: headache, diarrhea, and dizziness.
The most common side effects of donepezil HCl include: diarrhea, not wanting to eat (anorexia), and bruising.
These are not all the possible side effects of NAMZARIC.
NAMZARIC is a prescription medicine approved to treat moderate to severe Alzheimer’s disease in patients who are taking donepezil hydrochloride 10 mg, the active ingredient in Aricept®.
Please see full Prescribing Information, including Patient Information.
Aricept® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.